Heska Corporation Announces European Approval for PERIOceutic(TM) Gel

FORT COLLINS, Colo. (PROTEXT) - Heska Corporation (Nasdaq:HSKA), a leader in the companion animal health market, announcedtoday that its PERIOceutic(TM) Gel has been approved by theEuropean Commission for marketing and distribution in Europe. Theproduct is the first veterinary product indicated for thetreatment and control of periodontal disease in dogs. Robert Grieve, Chief Executive Officer of Heska, said, "We arevery pleased with the European marketing approval. We can nowmove forward to develop a relationship with a European marketingpartner for the PERIOceutic product. We are currently indiscussions with potential partners that have sales anddistribution networks throughout Europe." The PERIOceutic Gel product is similar to the ATRIDOX(R)subgingival antibiotic product developed for the human dentalmarket by Atrix Laboratories, Inc., and was exclusively licensedto Heska for veterinary applications. Heska introduced theproduct into the United States veterinary market in November1997. The product, manufactured for Heska by Atrix, is a gel-likesubstance containing the antibiotic doxycycline, that theveterinarian places beneath the gumline of the affected teeth.The product forms a slow release system delivering the antibioticinto the affected tissue, providing a local antimicrobial effectwhich lasts for several weeks. Periodontal disease is the mostcommonly diagnosed disease in dogs and is the primary cause oftooth loss. This new technology offers veterinarians a new toolto treat and control the disease, prevent tooth loss and guardagainst infection spreading to other parts of the body. Heska discovers, develops, manufactures and markets companionanimal health products, primarily for dogs, cats and horses.Heska has a large and sophisticated scientific effort devoted toapplying biotechnology to the large and growing companion animalhealth market. Heska also offers diagnostic and patientmonitoring equipment and supplies, as well as laboratorydiagnostic products in the United States and Europe toveterinarians, and operates USDA- and FDA-licensed facilities,which manufacture vaccine, pharmaceutical, and allergyimmunotherapy products. For additional information on Heska andits products, visit the company's web site at www.heska.com. With the exception of historical matters, this press releasecontains express or implied forward-looking information aboutHeska's products and markets, including statements concerning themarket acceptance of this product and potential Europeanpartners. Such forward-looking statements involve known andunknown risks, uncertainties and other factors which may causeactual results, performance or achievements of Heska to bematerially different from any future results, performance orachievements expressed or implied by such forward-lookingstatements. Heska's achievement of these results may be affectedby many factors, including among others, the following: delays inor failure to achieve market acceptance of this product; theinability to establish or maintain an effective distributionnetwork in Europe, delays in or failure to achieve future productdevelopment; uncertainties regarding the outcome of research anddevelopment efforts or the ability to successfully develop orcommercialize products in research and development, uncertaintiesregarding the ability to receive required regulatory approvals ina timely manner, if at all, uncertainties regarding the scope,enforceability and validity of patents and proprietary rights,which are subject to complex legal standards that vary fromcountry to country and are subject to interpretation byadministrative agencies and courts; quality of management;competition; changes in business strategy or development plans;inability to obtain renewal or continuation of contracts, orobtain exclusivity, to market, sell or distribute productsdescribed herein; inability to manufacture, market, sell ordistribute products at currently projected costs and the risksset forth in Heska's filings and future filings with theSecurities and Exchange Commission, including those set forth inHeska's Annual Report on Form 10-K for the year ended December31, 1998 under the caption "Business-Factors that May AffectResults," and in its Quarterly Report on Form 10-Q for thequarter ended June 30, 1999 under the caption "Management'sDiscussion and Analysis of Financial Condition and Results ofOperations - Factors that May Affect Results." ots Original TextService: Heska Corporation Internet: http://www.newsaktuell.deContact: Ron Hendrick, Executive Vice President & CFO, or RobertGrieve, Chief Executive Officer, 970-493-7272, both of HeskaCorporation; or Investor Relations: Judy Brenna, ext. 221, orMedia Relations: Matthew Knight, ext. 271, both of Noonan/RussoCommunications, Inc., 212-696-4455 Web site:http://www.heska.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT